Ranolazine Cardioprotection in PCI
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2015
At a glance
- Drugs Ranolazine (Primary)
- Indications Myocardial reperfusion injury
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 19 Nov 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 02 May 2013 Planned End Date (Nov 2013) added as reported by ClinicalTrials.gov.